Macedo Guilherme, Correia António, Ribeiro Tomé
Gastroenterology Unit, Hospital S. João, Porto, Portugal.
Hepatogastroenterology. 2003 Jul-Aug;50(52):1057-9.
BACKGROUND/AIMS: Several treatment schedules have been tried in acute hepatitis C, but due to the heterogeneity of included patients and to the non-practical interferon protocols, we assessed prospectively in a non-randomized pilot study, the efficacy of interferon 2b.
Five million units of interferon 2b were given three times weekly by subcutaneous route for 6 months as soon as diagnosis of acute hepatitis C was established.
In 6 jaundiced patients, we have achieved a rate of 83% of sustained response, for at least one year, with normalization of ALT and clearance of HCV RNA. Interferon was very well tolerated and there was no need for changing treatment schedule.
These findings suggest that 5 MU TIW for 6 months is well tolerated and effective in preventing, in a non-aggressive way, a chronic course of hepatitis C infection.
背景/目的：针对急性丙型肝炎已经尝试了多种治疗方案，但由于纳入患者的异质性以及干扰素方案不实用，我们在一项非随机的前瞻性初步研究中评估了干扰素2b的疗效。
一旦确诊急性丙型肝炎，立即每周皮下注射三次500万单位的干扰素2b，持续6个月。
在6例黄疸患者中，我们实现了83%的持续应答率，ALT恢复正常且HCV RNA清除，至少持续了一年。干扰素耐受性良好，无需改变治疗方案。
这些发现表明，6个月内每周三次500万单位的干扰素耐受性良好，且能以非激进的方式有效预防丙型肝炎感染的慢性病程。
